Details of the Drug Combination

General Information of Drug Combination (ID: DCLRRNL)

Drug Combination Name
JNK-IN-8 Bendamustine hydrochloride
Indication
Disease Entry Status REF
Adenocarcinoma Investigative [1]
Component Drugs JNK-IN-8   DMLWYJB Bendamustine hydrochloride   DMFH15Z
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL is unavailable
High-throughput Screening Result Testing Cell Line: HCT116
Zero Interaction Potency (ZIP) Score: 2.44
Bliss Independence Score: 0.33
Loewe Additivity Score: 2.45
LHighest Single Agent (HSA) Score: 4.26

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of JNK-IN-8
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [2]
JNK-IN-8 Interacts with 3 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Stress-activated protein kinase JNK3 (JNK3) TT056SO MK10_HUMAN Inhibitor [2]
JNK2 messenger RNA (JNK2 mRNA) TT3IVG2 MK09_HUMAN Inhibitor [2]
Stress-activated protein kinase JNK1 (JNK1) TT0K6EO MK08_HUMAN Inhibitor [2]
------------------------------------------------------------------------------------
JNK-IN-8 Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cell division cycle and apoptosis regulator protein 1 (CCAR1) OTUXLQZZ CCAR1_HUMAN Increases Expression [4]
------------------------------------------------------------------------------------
Indication(s) of Bendamustine hydrochloride
Disease Entry ICD 11 Status REF
leukaemia 2A60-2B33 Approved [3]
Bendamustine hydrochloride Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Modulator [3]
------------------------------------------------------------------------------------
Bendamustine hydrochloride Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [6]
------------------------------------------------------------------------------------
Bendamustine hydrochloride Interacts with 13 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Expression [5]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [5]
Beta-galactosidase (GLB1) OTB0TKAG BGAL_HUMAN Increases Expression [7]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [5]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Increases Activity [5]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Activity [5]
Caspase-6 (CASP6) OTXLD3EC CASP6_HUMAN Increases Activity [5]
Baculoviral IAP repeat-containing protein 3 (BIRC3) OT3E95KB BIRC3_HUMAN Decreases Expression [5]
Baculoviral IAP repeat-containing protein 2 (BIRC2) OTFXFREP BIRC2_HUMAN Decreases Expression [8]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Activity [5]
PRKC apoptosis WT1 regulator protein (PAWR) OTKY7W52 PAWR_HUMAN Decreases Expression [5]
Diablo IAP-binding mitochondrial protein (DIABLO) OTHJ9MCZ DBLOH_HUMAN Increases Localization [5]
Death domain-associated protein 6 (DAXX) OTX6O7PL DAXX_HUMAN Decreases Expression [5]
------------------------------------------------------------------------------------
⏷ Show the Full List of 13 DOT(s)

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Renal cell carcinoma DCXGYLZ UO-31 Investigative [9]
Adenocarcinoma DCNQBGM A549 Investigative [1]
High grade ovarian serous adenocarcinoma DCMU8JX OVCAR-4 Investigative [1]
Large cell lung carcinoma DCKOYSQ NCI-H460 Investigative [1]
Melanoma DC3HV3Y MALME-3M Investigative [1]
------------------------------------------------------------------------------------

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 Discovery of potent and selective covalent inhibitors of JNK. Chem Biol. 2012 Jan 27;19(1):140-54.
3 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
4 A H2AX?CARP-1 Interaction Regulates Apoptosis Signaling Following DNA Damage. Cancers (Basel). 2019 Feb 14;11(2):221. doi: 10.3390/cancers11020221.
5 Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activation. Biochem Pharmacol. 2003 Sep 1;66(5):711-24. doi: 10.1016/s0006-2952(03)00410-6.
6 Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites. Cancer Chemother Pharmacol. 2015 Jun;75(6):1143-54.
7 Chronic senescent human mesenchymal stem cells as possible contributor to the wound healing disorder after exposure to the alkylating agent sulfur mustard. Arch Toxicol. 2021 Feb;95(2):727-747. doi: 10.1007/s00204-020-02946-5. Epub 2021 Jan 25.
8 Upon drug-induced apoptosis in lymphoma cells X-linked inhibitor of apoptosis (XIAP) translocates from the cytosol to the nucleus. Leuk Lymphoma. 2004 Jul;45(7):1429-36. doi: 10.1080/1042819042000198858.
9 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.